Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Merck vaccine reduces infection in phase II
The phase II study evaluated the efficacy of Gardasil in preventing infection from the types of human papillomavirus (HPV) responsible for 70% of all cases of cervical cancer
The phase II study evaluated the efficacy of Gardasil in preventing infection from the types of human papillomavirus (HPV) responsible for 70% of all cases of cervical cancer
Under the agreement, Plexxikon’s libraries will be screened in parallel against the most therapeutically relevant kinase targets among a panel of 100 enzymes available currently. Plexxikon anticipates a
The Canadian patent represents the first patent covering bioactive natural products discovered using the company’s Decipher technology. Patent applications corresponding to the issued patent are pending in the
One of the studies revealed that patients taking olanzapine (Eli Lilly’s Zyprexa) or clozapine (Novartis’ Clozaril) remained on treatment longer than other atypicals (risperidone – Johnson & Johnson’s
The Texas Pharmacy Association (TPA) has unveiled an advertising campaign and a newly created patient bill of rights. The materials, which will be delivered to 1,200 pharmacies throughout
PRO 2000 is Indevus’ microbicide under development to prevent sexually acquired HIV infection and certain other sexually transmitted disease-causing viruses and bacteria. The phase III trial is designed
The amended agreement includes a reduction of future royalties payable to LG Life Sciences, an LG affiliate, at certain Factive (gemifloxacin mesylate) revenue levels in territories covered by
Hubei Jiuzhoutong Pharmaceutical Ltd is one of the largest and the fastest growing privately owned pharmaceutical distribution companies in China, with established sales and distribution networks throughout the
This investigator-sponsored trial marks an expansion by the company into a second form of cancer. The trial will test Argos’ RNA loaded autologous dendritic cell vaccine among patients
The phase I trial is a double-blind, placebo-controlled, single rising dose study designed to assess the safety and pharmacokinetics of INCB7839 in healthy volunteers. A phase I multiple